Navigation Links
Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
Date:11/28/2007

EMERYVILLE, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc (NTI (TM)) (Nasdaq: NTII) announced today that Warren Wasiewski, M.D. was appointed Chief Medical Officer, effective as of November 26, 2007.

Dr. Wasiewski joined NTI in February 2007 as Vice President, Clinical Programs with primary responsibility for running the clinical trial program for Viprinex(TM), NTI's drug candidate for acute ischemic stroke that is currently in two Phase 3 clinical trials. Dr. Wasiewski is a Board Certified Pediatric Neurologist with an extensive clinical career. Prior to joining NTI, he worked at AstraZeneca where he was Sr. Medical Director of clinical research CNS/Emerging Products. At AstraZeneca, Dr. Wasiewski had responsibility for running the global SAINT trials for AstraZeneca's neuroprotectant drug candidate.

Dr. Wasiewski holds a Bachelor of Arts degree in Biology Cum Laude from Rutgers College, a Masters of Science degree in Biochemistry from State University of New York Downstate Medical Center, and a Doctorate of Medicine from State University of New York, at Buffalo.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. PA Secretary of Public Welfare Responds to Warren State Hospital Closure Rumors
2. Governor Rendell Launches Tour to Insure in Warren County; Urges Passage of Plan to Give Access to Affordable Health Insurance
3. Friends of Warren Zevon To Play at Maverick Saloon - Raising Awareness of Asbestos Cancer, Mesothelioma
4. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
5. William Moore Appointed to IRIDEX Board of Directors
6. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
7. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
8. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
9. James B. Hawkins Appointed to IRIDEX Board of Directors
10. Bryan R. Rogers Appointed President of Far West Division
11. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users ... - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 ... Pro X . Simply select a ProHand generator and drag it above media or ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: